Lenalidomide Sandoz 2.5 Mg Hard Capsules

Lenalidomide, the active ingredient in Lenalidomide Sandoz 2.5 Mg Hard Capsules, is an immunomodulatory drug (IMiD) presented as a 2.5 mg hard capsule for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes in adult patients and is classified under ATC code L01XAB.

GNH USA supplies Lenalidomide Sandoz 2.5 Mg Hard Capsules as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, pharmacies and transplant centres worldwide. The company adheres to stringent quality standards and provides reliable global logistics.

Lenalidomide is an immunomodulatory agent used in specific hematologic malignancies. - Multiple Myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease. - Myelodysplastic Syndromes (del(5q) cytogenetic abnormality): reduces transfusion dependence and can lead to cytogenetic remission.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia - Fatigue - Nausea - Diarrhea

Serious or Rare Side Effects: - Venous thromboembolism - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome) - Secondary primary malignancies

When prescribing Lenalidomide, clinicians should observe several safety considerations. - Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Thrombotic risk assessment: evaluate patient history and consider prophylactic anticoagulation. - Renal and hepatic function: adjust therapy based on renal/hepatic impairment. - Pregnancy avoidance: the drug is contraindicated in pregnancy; ensure effective contraception. - Contraception requirement: both male and female patients of reproductive potential must use reliable contraception during treatment and for a defined period after discontinuation. - Store at below 25°C: keep in the original container, protect from moisture and light.

Lenalidomide has several clinically relevant drug interactions that require attention.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly lower lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Immunosuppressants (e.g., cyclosporine): may enhance toxicity.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): can raise plasma concentrations. - CYP3A4 inhibitors (e.g., ketoconazole): may increase drug exposure.